Drug guidance
Durvalumab in combination with tremelimumab for treating unresectable hepatocellular carcinoma
Condition
Cancer
Liver
4 June 2025
Published on 17 Feb 2025
Last Updated on 4 Jun 2025
Guidance Recommendations
The Ministry of Health’s Drug Advisory Committee has recommended:
Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, to be used according to the STRIDE regimen (single-dose tremelimumab in combination with regular-interval durvalumab) for treating unresectable hepatocellular carcinoma. Patients must not have received prior systemic therapy and must have adequate liver function as assessed by the Child-Pugh scoring system.
Funding status
Durvalumab 120 mg/2.4 mL and 500 mg/10 mL concentrate for solution for infusion, and tremelimumab 300 mg/15 mL concentrate for solution for infusion, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 August 2025.
Clinical indication, subsidy class and MediShield Life claim limits for durvalumab and tremelimumab are provided in the Annex.